Otsuka Holdings Toekomstige groei

Future criteriumcontroles 2/6

Otsuka Holdings zal naar verwachting groeien in winst en omzet met respectievelijk 10.5% en 0.6% per jaar. De winst per aandeel zal naar verwachting groeien met 11.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 9% zijn.

Belangrijke informatie

10.5%

Groei van de winst

11.1%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	11.9%
Inkomstengroei	0.6%
Toekomstig rendement op eigen vermogen	9.0%
Dekking van analisten	Good
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Earnings Miss: Otsuka Holdings Co., Ltd. Missed EPS By 10% And Analysts Are Revising Their Forecasts

Nov 04

Otsuka Holdings Co., Ltd. Just Beat EPS By 57%: Here's What Analysts Think Will Happen Next

Aug 05

Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 02

Recent updates

Earnings Miss: Otsuka Holdings Co., Ltd. Missed EPS By 10% And Analysts Are Revising Their Forecasts

Nov 04

Otsuka Holdings Co., Ltd. Just Beat EPS By 57%: Here's What Analysts Think Will Happen Next

Aug 05

Getting In Cheap On Otsuka Holdings Co., Ltd. (TSE:4578) Might Be Difficult

Jul 14

Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 02

Is There An Opportunity With Otsuka Holdings Co., Ltd.'s (TSE:4578) 24% Undervaluation?

Apr 20

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Mar 15

Winst- en omzetgroeiprognoses

TSE:4578 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2,290,424	247,660	223,463	N/A	9
12/31/2025	2,287,555	267,522	274,907	N/A	10
12/31/2024	2,277,142	230,444	167,766	N/A	8
9/30/2024	2,269,564	151,575	N/A	N/A	N/A
6/30/2024	2,179,961	126,817	N/A	N/A	N/A
3/31/2024	2,089,741	137,563	N/A	N/A	N/A
12/31/2023	2,018,568	121,616	N/A	N/A	N/A
9/30/2023	1,950,959	184,702	135,359	226,774	N/A
6/30/2023	1,871,228	166,860	122,224	206,555	N/A
3/31/2023	1,806,034	172,194	111,337	226,032	N/A
12/31/2022	1,737,998	133,906	N/A	N/A	N/A
9/30/2022	1,656,978	109,845	53,563	202,725	N/A
6/30/2022	1,593,768	103,809	72,220	219,752	N/A
3/31/2022	1,541,795	104,036	101,635	213,365	N/A
12/31/2021	1,498,276	125,463	115,712	228,864	N/A
9/30/2021	1,463,284	147,019	N/A	N/A	N/A
6/30/2021	1,446,198	152,734	N/A	N/A	N/A
3/31/2021	1,420,055	155,109	N/A	N/A	N/A
12/31/2020	1,422,826	148,137	N/A	N/A	N/A
9/30/2020	1,434,441	143,398	103,870	198,659	N/A
6/30/2020	1,420,552	146,198	131,591	216,159	N/A
3/31/2020	1,421,844	145,709	141,592	220,990	N/A
12/31/2019	1,396,240	127,151	N/A	N/A	N/A
9/30/2019	1,372,665	116,333	149,898	222,128	N/A
6/30/2019	1,344,787	86,379	112,554	183,817	N/A
3/31/2019	1,311,287	78,918	77,033	150,389	N/A
12/31/2018	1,291,981	82,492	62,213	135,821	N/A
9/30/2018	1,269,004	117,106	54,841	122,032	N/A
6/30/2018	1,262,916	133,942	N/A	93,786	N/A
3/31/2018	1,254,410	114,206	N/A	106,043	N/A
12/31/2017	1,239,952	112,492	N/A	102,832	N/A
9/30/2017	1,211,772	75,029	N/A	N/A	N/A
6/30/2017	1,196,154	88,267	N/A	104,452	N/A
3/31/2017	1,193,159	94,933	N/A	N/A	N/A
12/31/2016	1,195,547	92,563	N/A	142,004	N/A
9/30/2016	1,240,874	71,521	N/A	N/A	N/A
6/30/2016	1,294,177	61,301	N/A	119,802	N/A
3/31/2016	1,342,728	68,735	N/A	N/A	N/A
12/31/2015	1,445,227	84,053	N/A	253,873	N/A
12/31/2014	1,599,424	151,237	N/A	118,047	N/A
9/30/2014	1,541,631	163,443	N/A	178,279	N/A
6/30/2014	1,515,577	156,499	N/A	N/A	N/A
3/31/2014	1,452,759	150,956	N/A	226,461	N/A
12/31/2013	1,403,125	174,046	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 4578 ( 10.5% per jaar) ligt boven de spaarquote ( 0.3% ).

Winst versus markt: De winst van 4578 ( 10.5% per jaar) zal naar verwachting sneller groeien dan de JP markt ( 8.9% per jaar).

Hoge groeiwinsten: De winst van 4578 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 4578 ( 0.6% per jaar) zal naar verwachting langzamer groeien dan de markt JP ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van 4578 ( 0.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 4578 zal naar verwachting over 3 jaar laag zijn ( 9 %).

Otsuka Holdings Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Earnings Miss: Otsuka Holdings Co., Ltd. Missed EPS By 10% And Analysts Are Revising Their Forecasts

Price target increased by 7.8% to JP¥7,914

Otsuka Holdings Co., Ltd. Just Beat EPS By 57%: Here's What Analysts Think Will Happen Next

Price target increased by 9.7% to JP¥6,823

Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026

Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Recent updates

Earnings Miss: Otsuka Holdings Co., Ltd. Missed EPS By 10% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025

Otsuka Holdings Co., Ltd.'s (TSE:4578) Price In Tune With Earnings

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Price target increased by 7.8% to JP¥7,914

Calculating The Intrinsic Value Of Otsuka Holdings Co., Ltd. (TSE:4578)

Otsuka Holdings Co., Ltd. Just Beat EPS By 57%: Here's What Analysts Think Will Happen Next

First half dividend of JP¥60.00 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. (TSE:4578) announces an Equity Buyback for 10,000,000 shares, representing 1.84% for ¥50,000 million.

Now 21% undervalued

Otsuka Holdings Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Getting In Cheap On Otsuka Holdings Co., Ltd. (TSE:4578) Might Be Difficult

Price target increased by 9.7% to JP¥6,823

Upcoming dividend of JP¥60.00 per share

Now 22% undervalued

Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026

Now 21% undervalued

Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Is There An Opportunity With Otsuka Holdings Co., Ltd.'s (TSE:4578) 24% Undervaluation?

Final dividend of JP¥60.00 announced

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Otsuka Holdings Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Revises Dividend for the Full Year Ending December 31, 2023, Payable on March 29 , 2024

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023

Upcoming dividend of JP¥50.00 per share at 1.9% yield

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Now 21% undervalued

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half of Fiscal Year 2023

Otsuka Pharmaceutical Co., Ltd. Announces Positive Results of Phase III Trial in Japan Showing Reduced Agitation in Patients with Alzheimer's Dia Treated with Brexpiprazole

Upcoming dividend of JP¥50.00 per share at 1.8% yield

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Jul 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. Provides Dividend Guidance for Fiscal Year Ending 2023

Otsuka Pharmaceutical Co., Ltd. (Otsuka) Files an Application in Japan for an Additional Indication for Rexulti

Now 23% undervalued after recent price drop

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2022 Results on Feb 14, 2023

Upcoming dividend of JP¥50.00 per share

Now 21% undervalued

Otsuka Medical Devices Co., Ltd. and Recor Medical, Inc. Announce Submission of Application for Pre-Market Approval of the Paradise uRDN to the U.S. FDA

Otsuka Holdings Co., Ltd. Revises Consolidated earnings Guidance for the Fiscal Year Ending December 31, 2022

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Otsuka Holdings Co., Ltd. Revises Consolidated Earrings Guidance for the Fiscal Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month by Otsuka America Pharmaceutical, Inc

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ended June 30, 2022

Price target increased to JP¥4,725

Otsuka Holdings Co., Ltd. to Report Q2, 2022 Results on Jul 29, 2022

Upcoming dividend of JP¥50.00 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter of Fiscal Year Ending December 31, 2022; Provides Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q1, 2022 Results on May 13, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind